Why the study?
Do different classes of lipid-lowering therapy (statins vs PCSK9 inhibitors) increase the risk of hemorrhagic stroke in high-risk patients?
Do different classes of lipid-lowering therapy (statins vs PCSK9 inhibitors) increase the risk of hemorrhagic stroke in high-risk patients?
Answers are grounded in this paper and cite their sources.
PCSK9 inhibitors may be the preferred lipid-lowering therapy for patients with an elevated risk of hemorrhagic stroke, as they do not appear to increase this risk unlike statins.
Statins increase the risk of HS in a medication dose- and type of index brain vascular injury-dependent manner; PCSK9Is do not increase HS risk. PCSK9Is may be a preferred lipid-lowering medication class in patients with elevated HS risk, including patients with prior HS.
No takes yet. Share an insight, caveat, or question.
Cuesta et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: